IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Opus Genetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.82−0.02 (-0.52%)
Close on Oct 19, 2026
- Market cap
- $425.49M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Opus Genetics has not reported a dividend
No dividend per share appears in Opus Genetics's annual filings since fiscal 2010.